Patients with adult-onset Still's disease were much more likely to achieve sustained remission when they were initially ...

Biologic therapy was associated with more than seven times greater odds of reaching sustained remission compared with ...

“Exciting” data were presented on emapalumab in the treatment of refractory macrophage activation syndrome (MAS) in patients with sJIA/Still disease. And the FDA approved three new drugs for JIA.